Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Earnings Results

Enanta Pharmaceuticals (NASDAQ:ENTA) released its earnings results on Monday. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.11, Zacks reports. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA opened at $4.90 on Tuesday. Enanta Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $17.80. The stock has a 50-day moving average price of $5.94 and a two-hundred day moving average price of $9.68.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 13.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ENTA shares. HC Wainwright lowered their target price on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, December 24th. JMP Securities reissued a “market outperform” rating and set a $21.00 price objective (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, Robert W. Baird cut their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.